RxSight (RXST) AI Stock Analysis

• Market Cap: $505.12M
• Dividend Yield: N/A
• Average Volume (3M): 646.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: 46.69%
• EPS Growth: 46.68%
• Country: US
• Employees: 498
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): -0.20
• Shares Outstanding: 40,636,982
• 10 Day Avg. Volume: 700,623
• 30 Day Avg. Volume: 646,814
• PEG Ratio: -0.15
• Price to Book (P/B): 3.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.72
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 0.67
• Enterprise Value/Gross Profit: 3.60
• Enterprise Value/Ebitda: -3.52
• 1Y Price Target: $11.79
• Price Target Upside: 48.30% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 9

• Rating: 43 Neutral
• Price Target: $7.50 ▼(-5.66%Downside)

The overall stock score reflects a mix of strong revenue growth and customer satisfaction, offset by significant operational and profitability challenges. Bearish technical signals and a negative valuation picture further contribute to the lower score.

Positive Factors

Market Opportunity

International markets represent a significant opportunity for RxSight, with plans to enter European and Asian markets where the advanced technology IOL market is twice the size of the US market.

Valuation

RxSight's valuation appears very attractive, trading at a significant discount to its peers, with above-average growth, a strong moat, and high gross margins.

Negative Factors

Financial Performance

RxSight preannounced Q2 revenue of $33.6m, missing Street consensus by $6m or 16%.

Market Competition

Increased competitive pressures from recent multifocal IOL launches are impacting RxSight.

RxSight Business Overview & Revenue Model

Company Description

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

How the Company Makes Money

RxSight generates revenue primarily through the sale of its Light Adjustable Lens (LAL) and associated Light Delivery Device (LDD) systems. These products are sold to ophthalmologists and eye surgery centers, providing a unique value proposition by enabling customized vision correction after cataract surgery. The company also earns revenue from service agreements and follow-up care related to its product offerings. Strategic partnerships with eye care professionals and healthcare facilities further enhance RxSight's market reach and revenue potential.

RxSight Financial Statement Overview

Summary

RxSight demonstrates strong revenue growth and a solid balance sheet with low leverage. However, persistent profitability issues and negative cash flows present significant challenges.

Income Statement

RxSight has shown impressive revenue growth, with TTM revenue up by 13.2%. However, the company is struggling with profitability, as evidenced by negative EBIT and net income margins. The gross profit margin is healthy at 67.3% TTM, indicating good control over cost of goods sold, but the negative EBIT and net income margins highlight ongoing operational challenges.

Balance Sheet

The company maintains a strong equity position, with a debt-to-equity ratio of 0.04 TTM, indicating low financial leverage. The equity ratio of 89.2% TTM suggests a stable balance sheet with a solid asset base funded primarily by equity. Despite these strengths, the company is not yet profitable, which could pose future risks.

Cash Flow

Free cash flow remains negative, although there is an improvement in operating cash flow compared to the previous year, indicating better cash management. The operating cash flow to net income ratio is negative, reflecting ongoing cash flow challenges. The free cash flow to net income ratio is also negative, underlining the need for improved cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	158.40M	139.93M	89.08M	49.01M	22.59M	14.68M
Gross Profit	106.59M	98.94M	53.77M	21.33M	4.52M	1.71M
EBITDA	-26.49M	-23.76M	-41.04M	-57.78M	-41.01M	32.15M
Net Income	-26.55M	-27.45M	-48.61M	-66.76M	-48.69M	27.57M
Balance Sheet
Total Assets	313.04M	318.56M	182.55M	150.16M	192.72M	100.68M
Cash, Cash Equivalents and Short-Term Investments	229.34M	237.22M	127.18M	105.80M	159.33M	68.97M
Total Debt	12.04M	12.30M	3.01M	44.99M	44.93M	30.75M
Total Liabilities	33.73M	37.33M	22.19M	60.26M	54.48M	398.21M
Stockholders Equity	279.32M	281.24M	160.36M	89.90M	138.24M	-297.53M
Cash Flow
Free Cash Flow	-20.60M	-22.39M	-46.41M	-61.24M	-46.65M	-37.74M
Operating Cash Flow	-16.55M	-16.95M	-41.59M	-58.85M	-44.71M	-35.20M
Investing Cash Flow	-102.73M	-99.31M	-22.13M	39.95M	-81.91M	15.59M
Financing Cash Flow	114.67M	123.32M	61.52M	6.33M	137.34M	25.24M

RxSight Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RXST, the sentiment is Negative. The current price of 7.95 is below the 20-day moving average (MA) of 13.30, below the 50-day MA of 14.30, and below the 200-day MA of 30.38, indicating a bearish trend. The MACD of -1.01 indicates Positive momentum. The RSI at 18.21 is Positive, neither overbought nor oversold. The STOCH value of 16.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RXST.

RxSight Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIBN	65 Neutral	$774.31M	―	-15.96%	―	22.60%	41.26%
AXGN	61 Neutral	$517.38M	―	-7.22%	―	18.81%	67.41%
CBLL	54 Neutral	$621.66M	―	26.25%	―	―	―
BVS	50 Neutral	$560.22M	―	-19.79%	―	8.60%	-42.76%
OFIX	49 Neutral	$443.14M	―	-27.82%	―	5.85%	-8.92%
Sector *	46 Neutral	C$198.48M	-3.49	-23.22%	2.62%	21.07%	-1.26%
RXST	43 Neutral	$505.12M	―	-11.98%	―	46.69%	46.68%

RxSight Corporate Events

RxSight Re-elects Directors at Annual Meeting

RxSight held its 2025 Annual Meeting of Stockholders on June 3, 2025, where approximately 79.2% of the outstanding shares were represented. During the meeting, three Class I directors, Ron Kurtz, M.D., J. Andy Corley, and Juliet Tammenoms Bakker, were re-elected to serve until the 2028 annual meeting. Additionally, the stockholders approved the executive compensation and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (RXST) stock is a Buy with a $73.00 price target. To see the full list of analyst forecasts on RxSight stock, see the RXST Stock Forecast page.